8-K filing — First Tracks Biotherapeutics, Inc. (TRAX)
Filed: 2026-10-20 AccNo: 0001193125-26-426666 Size: 446 KB Item 1.01: Entry into a Material Definitive Agreement Item 9.01: Financial Statements and Exhibits
Stocks · News reference
First Tracks Biotherapeutics shares are trading higher after the company reported Phase 1b data showing ANB033 achieved statistically significant improvements versus placebo across key histologic and symptom endpoints in celiac disease.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Leerink Partners Maintains Outperform on First Tracks, Raises Price Target to $90
Leerink Partners analyst David Risinger maintains First Tracks (NASDAQ:TRAX) with a Outperform and raises the price target from $70 to $90.
First Tracks Biotherapeutics Announces ~$200M Private Placement Of 6,106,870 Shares At $32.75/Share To Institutional Investors
First Tracks Biotherapeutics, Inc. (NASDAQ:TRAX), a clinical stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases, today announced
Canaccord Genuity Maintains Buy on First Tracks, Raises Price Target to $60
Canaccord Genuity analyst Edward Nash maintains First Tracks (NASDAQ:TRAX) with a Buy and raises the price target from $50 to $60.